News & Resources

Biotechnology Value Fund’s Investments Highlighted

February 18, 2010

Elsevier’s In Vivo Blog recently featured Olshan's client, Biotechnology Value Fund in an article about the Fund’s investments in various pharmaceutical related companies including Addex Pharmaceuticals, a Swiss pharmaceuticals company; Celera Corporation, a diagnostics company focused on genetic sequencing and Facet Biotech which is focused on oncology therapeutics. The article also discusses the Fund’s recent involvement with Avigen, Inc. and the Fund’s role in successfully merging Avigen with MediciNova, Inc.

Adam W. Finerman and Jason W. Soncini represented Biotechnology Value Fund in these transactions.

Attorneys